Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1645-1653

  Nixon, Donald R ^a   Yan, David B ^b   Chartrand, Jean Pierre ^a,c   Piemontesi, Roberto L ^a   Simonyi, Susan ^d   Hollander, David A ^d  

^a University of Toronto ^*

^b UNIVERSITY OF TORONTO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ALLERGAN INC   (United States)

Author keywords

Brimonidine; Dorzolamide; Fixed combination; Glaucoma; Intraocular pressure; Timolol

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; BLURRED VISION; BURNING SENSATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TASTE DISORDER; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; QUINOXALINES; SULFONAMIDES; THIOPHENES; TIME FACTORS; TIMOLOL;

EID: 67650469667     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902994041     Document Type: Conference Paper

References (21)

1. Jampel HD. Target pressure in glaucoma therapy. J Glaucoma 1997;6:133-8
2. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. An evidence-based review. Ophthalmology 2005;112:953-61
3. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
4. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
5. Katz LJ, Simmons ST, Craven ER. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension. Curr Med Res Opin 2007; 23:2971-83
6. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14
7. Arcieri ES, Arcieri RS, Pereira AC, et al. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 2007;23:683-9
8. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615-24
9. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/ timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149-57
10. McKee HD, Gupta MS, Ahad MA, et al. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye 2005;19:923-24
11. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6
12. Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother 2008;42:498-504
13. Crichton ACS. Timolol/brimonidine combination therapy in glaucoma management. Clin Surg J Ophthalmol 2005;23:356-9
14. Ahmed I. CEED II: an in-depth look at the latest findings. Clin Surg J Ophthalmol 2007;25:1-5
15. Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther 2007;23:372-6
16. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
17. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
18. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study Group. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008;126:1030-6
19. Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma 2004;13:130-6
20. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
21. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma 2000;9:235-8